The Eye That Remembers: Could ER-100 Restore Lost Vision?

By James Clayton – TheFutureBaby.com

I have a personal reason for following the effort to restore damaged eyesight.

Years ago, I was shot in the left eye with a BB gun. Doctors managed to save the eye, but as part of that process, I was kept medically blind for roughly two weeks. I did not permanently lose my sight, but during those two weeks, I experienced what it was like to live without it.

It changes your understanding of blindness. Sight is easy to take for granted until the visible world suddenly disappears. Even temporarily losing it made me realize how much of our independence and connection to everything around us depends upon two extraordinarily fragile organs.

Today, my left eye is blurry while my right eye is not. That could be related to the old injury, or it could be a coincidence. During a recent examination, an optometrist also noticed unusual circles in my left eye. I believe they may be remnants of the BB impact, although that has not been medically confirmed.

Whatever the cause of the blurriness, I was fortunate. Doctors saved my eye, and I did not permanently lose my sight.

That experience makes the possibility of restoring vision deeply personal to me. Giving sight back to someone who has lost it would seem almost miraculous.

An experimental treatment called ER-100 may be an early step toward making that possible.

Restoring Sight Instead of Slowing Its Loss

ER-100 is being developed by Life Biosciences, a company co-founded by Harvard Medical School professor of genetics David Sinclair. It is being tested as a possible treatment for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, known as NAION.

Glaucoma slowly damages the optic nerve and is a leading cause of blindness. Current treatments can lower pressure inside the eye and slow the disease, but they cannot reliably restore nerve cells that have already been lost.

NAION is sometimes described as a “stroke of the eye.” It happens when blood flow to the optic nerve is impaired, causing sudden and usually painless vision loss. There is currently no approved treatment that can reverse the damage.

Both conditions can damage retinal ganglion cells. These are nerve cells that carry visual information from the eye toward the brain. Once they are badly damaged or destroyed, they have very little natural ability to regenerate.

ER-100 is an attempt to change that.

Reminding Old Cells How to Be Young

Our DNA can be compared to a massive instruction manual. Nearly every cell carries essentially the same manual, but different cells read different sections. A nerve cell follows one set of instructions, while a skin or liver cell follows another.

As we age, the system that controls those instructions changes. One hypothesis is that aging cells still retain much of the epigenetic information associated with youth but gradually lose the ability to use that information correctly.

David Sinclair and other researchers have proposed that the progressive loss of epigenetic information may be one contributor to aging.

ER-100 uses three genes—OCT4, SOX2, and KLF4—to partially reprogram cells. Together, they are called OSK.

The goal is not to turn the cell completely back into a stem cell. That could erase its identity and create serious risks. Instead, the treatment attempts a partial reset: restoring more youthful patterns of gene activity while allowing the cell to retain its identity.

ER-100 is administered as a single intravitreal injection into one eye. A modified adeno-associated virus, or AAV, carries the genetic instructions for OSK into retinal cells. AAV vectors are widely studied as delivery vehicles in gene therapy and are engineered to deliver genetic material without causing the disease associated with naturally occurring viruses.

ER-100 is also designed so that OSK expression can be controlled. Participants receive doxycycline for eight weeks after treatment to activate the system, giving researchers control over when the OSK factors are expressed.

In simple terms, ER-100 attempts to remind damaged or aging cells how they functioned when they were younger.

What Scientists Have Seen So Far

In a 2020 study published in Nature, researchers tested OSK-based partial reprogramming in mice. The treatment promoted regeneration of damaged optic-nerve axons and improved visual function in aged mice and in a mouse model of glaucoma. The researchers also reported changes toward more youthful patterns of gene expression and DNA methylation.

That was an extraordinary result, but mice are not humans. Many treatments work in mice and later fail in people.

Researchers then moved to nonhuman primates, whose eyes and visual systems are more similar to ours. In research presented at the 2023 Association for Research in Vision and Ophthalmology meeting, Life Biosciences and academic collaborators reported that OSK treatment significantly improved pattern electroretinogram responses and increased the number of healthy optic-nerve axon bundles in primates with experimentally induced optic-nerve damage designed to model NAION.

Those results were encouraging enough to help support the move toward human testing, but the primate findings were preclinical results presented at a scientific meeting, not proof that the therapy would work in people.

In January 2026, the FDA cleared ER-100 to begin its first human clinical trial. In June, Life Biosciences announced that the first participant had received the treatment.

The Phase 1 trial is expected to enroll up to 18 participants: 12 with open-angle glaucoma and six with NAION. Its primary purpose is to determine whether ER-100 is safe and tolerable, although researchers will also measure visual function and look for evidence that the treatment may be helping.

This is an important distinction: FDA permission to begin a trial is not FDA approval of the treatment. ER-100 has not yet been proven safe or effective, and it has not yet been shown to restore vision in a human being.

The first question is whether scientists can safely reset these cells.

The second is whether doing so can restore meaningful vision.

What This Could Mean Beyond the Eye

ER-100 is not being tested for every kind of blindness. Eye damage can involve the cornea, lens, retina, optic nerve, or even the parts of the brain that process vision. A treatment that helps one type of nerve cell will not necessarily repair every form of damage.

I would not assume that ER-100 could correct the blurriness in my left eye or erase the circles my optometrist observed. The trial is not studying old BB injuries, and I do not know whether the injury caused either condition.

My connection is personal. I know what happened to my eye, and I remember what it was like to experience temporary blindness. That is enough to make the goal of restoring sight meaningful to me.

The eye is also a logical place to begin testing cellular rejuvenation. It is small and accessible, treatment can be delivered directly to it, and changes in visual function can be carefully measured.

But if the basic idea works, the importance could extend far beyond eyesight.

If scientists can restore more youthful function to damaged human nerve cells, it would suggest that some forms of age-related cellular decline may be more reversible than previously assumed. Old cells may still retain a kind of biological memory of youth—and medicine may eventually learn how to access it.

That would not mean whole-body age reversal had arrived. Treating the heart, brain, kidneys, muscles, and immune system would present much greater challenges. It could take decades and require many different technologies.

Still, every medical revolution begins with a first successful step.

Restoring vision through partial cellular reprogramming would matter not because it completes the journey, but because it would provide evidence that the road exists.

A Miracle Made in a Laboratory

When I think back to those two weeks without sight, I remember how dependent we are on a biological system that most of us barely notice.

I was fortunate because my blindness was temporary. Doctors saved my eye, and I eventually saw the world again. Even if my left eye remains blurry today, I can still see. That is not a small thing.

Millions of people live with vision loss that medicine can sometimes slow but cannot reverse. Restoring their sight would not be a minor improvement recorded on a medical chart.

It could mean seeing a loved one’s face, reading, driving, navigating a room independently, or watching the sun set again.

ER-100 may fail. It may prove safe but only modestly effective. It may preserve remaining vision without restoring what has already been lost. Honest science requires us to accept all of those possibilities.

But there is another possibility: old or injured human cells may retain biological information associated with a younger, healthier state.

If ER-100 can safely access even part of that information and return meaningful sight, it could become more than a new treatment for two eye diseases. It could provide important human evidence that partial epigenetic reprogramming can restore function in cells damaged by aging or disease—and suggest that aspects of cellular aging may be medically adjustable.

Restoring sight to the blind would already be a miracle.

It may also illuminate the path toward regenerating much more of the human body.

Sources

Lu Y, et al. “Reprogramming to Recover Youthful Epigenetic Information and Restore Vision.” Nature, 2020.

ClinicalTrials.gov. “Evaluating ER-100 for Safety in People With Glaucoma or NAION.” Trial NCT07290244.

Life Biosciences. FDA clearance announcement for the ER-100 Investigational New Drug application, January 28, 2026.

Life Biosciences. First participant dosed in the Phase 1 ER-100 trial, June 9, 2026.

Ksander B, et al. “A Novel Gene Therapy That Restores Vision Loss in a Nonhuman Primate Model of NAION by Epigenetic Reprogramming.” Presented at the Association for Research in Vision and Ophthalmology meeting, 2023.